Veklury
Total Payments
$126.2M
Transactions
13,168
Doctors
5,172
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.2M | 2,297 | 1,210 |
| 2023 | $1.3M | 4,108 | 2,222 |
| 2022 | $4.9M | 2,359 | 1,309 |
| 2021 | $20.0M | 3,099 | 1,277 |
| 2020 | $97.8M | 1,305 | 30 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $123.5M | 3,017 | 97.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 565 | 1.0% |
| Consulting Fee | $893,975 | 495 | 0.7% |
| Travel and Lodging | $329,752 | 833 | 0.3% |
| Food and Beverage | $329,342 | 7,315 | 0.3% |
| Education | $12,290 | 940 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $7,000 | 3 | 0.0% |
Payments by Type
Research
$123.5M
3,017 transactions
General
$2.8M
10,151 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| The Simple Study in Coronavirus, Severe Subjects | Gilead Sciences, Inc. | $80.3M | 0 |
| Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting | Gilead Sciences, Inc. | $11.1M | 1 |
| The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | Gilead Sciences, Inc. | $10.2M | 0 |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19 | Gilead Sciences, Inc. | $5.4M | 0 |
| A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19 | Gilead Sciences, Inc. | $3.9M | 0 |
| A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation | Gilead Sciences, Inc. | $3.0M | 1 |
| A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants from Birth to < 18 Years of Age with COVID-19 | Gilead Sciences, Inc. | $2.4M | 0 |
| A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and Metabolites in Participants with Normal Renal Function and Renal Impairment | Gilead Sciences, Inc. | $2.3M | 0 |
| A Phase 1 Open-Label, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics of Remdesivir and its Metabolite(s) in Subjects with Normal Hepatic Function and Hepatic Impairment. | Gilead Sciences, Inc. | $1.3M | 0 |
| A Phase 1, Randomized, Placebo- and Positive-Controlled Study to Evaluate the Effect of Remdesivir on the QT/QTc Interval in Healthy Participants | Gilead Sciences, Inc. | $1.1M | 0 |
| IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States | Gilead Sciences, Inc. | $832,794 | 0 |
| SARS-CoV-2 Viral Dynamics and Evolution in Response to Remdesivir Treatment | Gilead Sciences, Inc. | $247,366 | 0 |
| RDV Infusion Therapy Outside the Traditional Hospital Setting | Gilead Sciences, Inc. | $232,545 | 0 |
| Natural History of SARS-CoV-2 Infection in Varied Clinical Settings | Gilead Sciences, Inc. | $231,634 | 0 |
| Real World Data Observational Study of COVID-19 in a Flyover Region | Gilead Sciences, Inc. | $224,274 | 0 |
| The effect of remdesivir on COVID-19 outcomes in patients with acute and chronic kidney disease | Gilead Sciences, Inc. | $218,010 | 0 |
| Therapeutic management of patients with COVID-19 in a Large, Academic Medical Center | Gilead Sciences, Inc. | $122,980 | 0 |
| Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir | Gilead Sciences, Inc. | $118,000 | 0 |
| Remdesivir for Treatment of COVID-19: Real World Data in a Predominantly Black and Latino Population | Gilead Sciences, Inc. | $104,708 | 0 |
| Will Antiviral Treatment with Remdesivir during Acute COVID-19 Reduce the Incidence of Long COVID? A retrospective cohort analysis of hospitalized patients with COVID-19 in the Providence St. Joseph Health system. | Gilead Sciences, Inc. | $80,000 | 0 |
Top Doctors Receiving Payments for Veklury
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, MN | $123.3M | 3,015 |
| , M.D | Internal Medicine | Livingston, NJ | $236,237 | 189 |
| , MD | Internal Medicine | Bakersfield, CA | $204,322 | 29 |
| , M.D | Pulmonary Disease | Los Angeles, CA | $147,631 | 96 |
| , MD | Emergency Medicine | Holmdel, NJ | $101,191 | 123 |
| , MD | Family Medicine | Orange, CA | $95,759 | 102 |
| , M.D. PH.D | Internal Medicine | Asheville, NC | $91,424 | 57 |
| , MD | Sleep Medicine | W Hollywood, CA | $74,206 | 76 |
| , MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $66,668 | 94 |
| , M.D | Internal Medicine | Chicago, IL | $60,540 | 87 |
| , MD | Pediatrics | Stanford, CA | $56,837 | 47 |
| , MD | Infectious Disease | New Haven, CT | $56,569 | 60 |
| , M.D | Internal Medicine | Douglasville, GA | $49,353 | 46 |
| , M.D | Infectious Disease | Lexington, KY | $46,841 | 71 |
| , MD | Pulmonary Disease | Chicago, IL | $46,791 | 38 |
| , MD | Infectious Disease | San Diego, CA | $39,662 | 46 |
| , M.D | Emergency Medical Services | Lafayette, LA | $39,405 | 77 |
| Elizabeth Jenny-Avital | Internal Medicine | Bronx, NY | $39,084 | 58 |
| , DO | Internal Medicine | Sterling Heights, MI | $36,194 | 51 |
| , M.D | Infectious Disease | Fort Worth, TX | $35,911 | 49 |
| , MD | Internal Medicine | Temple Terrace, FL | $34,502 | 58 |
| , M.D | Infectious Disease | Newburyport, MA | $33,812 | 50 |
| , M.D., M.P.H | Internal Medicine | Seattle, WA | $31,675 | 36 |
| , M.D | Internal Medicine | Milwaukee, WI | $29,158 | 31 |
| , MD | Infectious Disease | New Britain, CT | $26,948 | 39 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $126.2M
Product Information
- Type Drug
- Total Payments $126.2M
- Total Doctors 5,172
- Transactions 13,168
About Veklury
Veklury is a drug associated with $126.2M in payments to 5,172 healthcare providers, recorded across 13,168 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences, Inc..
Payment data is available from 2020 to 2024. In 2024, $2.2M was paid across 2,297 transactions to 1,210 doctors.
The most common payment nature for Veklury is "Unspecified" ($123.5M, 97.8% of total).
Veklury is associated with 20 research studies, including "The Simple Study in Coronavirus, Severe Subjects" ($80.3M).